- Home
- RNTX vs NYC Comparison
RNTX vs NYC Comparison
Compare RNTX & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- NYC
- Stock Information
- Founded
- RNTX 2001
- NYC 2013
- Country
- RNTX United States
- NYC United States
- Employees
- RNTX N/A
- NYC N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- NYC Real Estate
- Sector
- RNTX Health Care
- NYC Finance
- Exchange
- RNTX Nasdaq
- NYC Nasdaq
- Market Cap
- RNTX 40.3M
- NYC 40.9M
- IPO Year
- RNTX N/A
- NYC N/A
- Fundamental
- Price
- RNTX $1.16
- NYC $12.82
- Analyst Decision
- RNTX
- NYC
- Analyst Count
- RNTX 0
- NYC 0
- Target Price
- RNTX N/A
- NYC N/A
- AVG Volume (30 Days)
- RNTX 56.1K
- NYC 2.3K
- Earning Date
- RNTX 08-13-2025
- NYC 08-08-2025
- Dividend Yield
- RNTX N/A
- NYC N/A
- EPS Growth
- RNTX N/A
- NYC N/A
- EPS
- RNTX N/A
- NYC N/A
- Revenue
- RNTX N/A
- NYC $58,397,000.00
- Revenue This Year
- RNTX N/A
- NYC $8.40
- Revenue Next Year
- RNTX N/A
- NYC $1.62
- P/E Ratio
- RNTX N/A
- NYC N/A
- Revenue Growth
- RNTX N/A
- NYC N/A
- 52 Week Low
- RNTX $1.04
- NYC $7.89
- 52 Week High
- RNTX $4.40
- NYC $16.30
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- NYC 44.68
- Support Level
- RNTX N/A
- NYC $12.63
- Resistance Level
- RNTX N/A
- NYC $13.25
- Average True Range (ATR)
- RNTX 0.00
- NYC 0.64
- MACD
- RNTX 0.00
- NYC -0.26
- Stochastic Oscillator
- RNTX 0.00
- NYC 32.47
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.